MedTrace Logo

CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects

NCT03713892 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2020-02-24

No results posted yet for this study

Summary

To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of CKD-504 compared to placebo in healthy Korean and Caucasian adult subjects

Conditions

  • Huntington Disease

Interventions

DRUG

CKD-504

orally administered once with investigational drug assigned on 1d morning with 240 mL of water

DRUG

Placebo

orally administered

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Kyung-Sang Yu · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-23
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03713892 on ClinicalTrials.gov